Piramal Pharma Solutions Integrated Contract Pharmaceutical Development, Clinical Services and Commercial Manufacturing

Piramal Healthcare is a leading provider of contract development, clinical services and commercial manufacturing to the global pharmaceutical industry. Situated in the north-east of England, Piramal offers commercial API manufacturing, pre-clinical pharmaceutical development through to Phase III supplies which can be coupled with clinical trial packaging and distribution, and finally commercial pharma manufacturing, packaging and distribution – all from the same facility.

Piramal’s site operates to the highest standards of GMP and quality with recent FDA and MHRA inspections. Providing services to over 30 companies, and more than 100 markets, the ability to integrate development and manufacturing services from the same location simplifies the customer’s supply chain. Piramal’s aim is to work with its customers in such a way that it acts as a virtual extension of the customers’ own operations.

API commercialisation services

Piramal’s commercial API capabilities support the following:

  • Typical product volume range from 50kg/annum-5,000kg/annum
  • Phase III manufacturing supplies
  • Launch or late lifecycle products
  • Up to Safebridge Band 3 (0.1µg/m³)
  • A finishing facility capable of handling parenteral API
  • DMF / CEP / CMC generation
  • Worldwide sales of Misoprostol and Spironolactone (the latter through Pfizer PCS)
  • Technology transfer and process optimisation
  • MHRA and FDA approvals

Pharmaceutical development services

Piramal offers a comprehensive range of pharmaceutical development capabilities and experience:

  • Phase I solid drugs
  • Material physical characterisation
  • Pre-formulation
  • Solid dosage and powder manufacturing
  • Specialist hormonal product capabilities
  • Ability to handle controlled substances
  • Placebo manufacture
  • Clinical batch manufacture
  • Over-encapsulation
  • Analytical method development and validation
  • Cleaning method development
  • Stability studies to ICH requirements
  • Process optimisation and validation
  • IMP QP release services
  • CMC, ANDA and IMPD generation

Commercial manufacturing of solid dosage forms

Piramal’s capabilities for commercial manufacturing of solid dosage forms include:

  • High and low-shear granulation
  • Roller compaction
  • Fluid bed granulation
  • Forced-air oven drying
  • Fluid bed drying
  • Powder blending and milling
  • Compression
  • Encapsulation
  • Dry coating
  • Film coating
  • High-speed blister packaging (cold form or thermoform)
  • Bottle line packaging capable of handling glass and plastic containers
  • MHRA and FDA approvals
  • Analytical testing and ongoing stability programmes
  • QP release services

Piramal offers rapid, efficient technology transfer of commercial products and a track record of client satisfaction.

Clinical trial packaging services

Piramal’s dedicated clinical trial services suite specialises in manufacturing and placebo matching for clinical trials, the design of custom solutions for the packaging and worldwide distribution of clinical trial materials, and in providing a range of associated services, including comparator sourcing, stability testing, formulation development and analytical method development. Services include:

  • Drug medication sourcing
  • Over-encapsulation and product blinding
  • Solid dose bottling and multi-dose blistering capabilities
  • Label design and printing for open and randomised studies
  • Labelling and assembly of patient kits
  • Translation services
  • Storage and global distribution capabilities
  • Real-time, fully integrated protocol tracking system
  • Protocol inventory management to the patient kit level
  • Post-study drug returns, reconciliation and destruction
  • Full supply-chain QP declaration and certification
  • Analytical method development and drug stability programmes
  • Integrated global quality system, including QP presence in the UK and North America

Global contract pharmaceutical development, clinical services and commercial manufacturing services

Piramal can seamlessly integrate services across its global network of assets in North America, the UK, India and China, and provides its customers with geographical flexibility, reduction in drug development times and cost competitiveness across the product lifecycle, while maintaining high levels of service reliability and quality.

Make an enquiry

Piramal Pharma Solutions Inc.

1500 Bull Lea Road

Suite 250,

Lexington, KY 40511

United States of America

+1 859 977 8600 www.piramalpharmasolutions.com

Piramal Pharma Solutions Images

Products and Services


White Papers

Related Projects

Zepatier for the Treatment of Chronic Hepatitis C Genotype 1 and 4 Infection

Zepatier is a once-daily oral medicine comprising 50mg of non-structural protein 5A (NS5A) replication complex inhibitor elbasvir and 100mg of NS3/4A protease inhibitor grazoprevir.

3rd July 2018

Parsabiv™ (etelcalcetide) for the Treatment of Secondary Hyperparathyroidism (SHPT)

Parsabiv™ (etelcalcetide) is an intravenous injectable calcimimetic agent developed by Amgen for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) that were previously treated with haemodialysis.

1st June 2018

ADYNOVI for the Treatment of Adults and Adolescents with Haemophilia A

ADYNOVI® is an intravenous infusion indicated for the treatment of adults and adolescents with haemophilia A.

2nd May 2018

Steglatro (ertugliflozin) for the Treatment of Type 2 Diabetes

Steglatro™ (ertugliflozin) is a combination drug indicated for the improvement of glycaemic control in adult patients with Type 2 diabetes mellitus.

2nd April 2018

Ibrance (palbociclib) for the Treatment of Metastatic Breast Cancer

Ibrance (palbociclib) is an oral formulation developed by Pfizer for the treatment of metastatic breast cancer in women with disease progression post endocrine therapy.

29th September 2016

Nuwiq, Anti-Haemophilic Factor (recombinant) for the Treatment of Haemophilia A

Nuwiq injection is the first recombinant anti-haemophilic factor (blood coagulation factor VIII) drug indicated for the treatment of patients with haemophilia A.

18th February 2016

Eliquis (apixaban) for Prevention of Stroke in Nonvalvular Atrial Fibrillation (NVAF) Patients

Eliquis (apixaban) is an anticoagulant drug that was jointly developed by Bristol-Myers Squibb and Pfizer.

3rd February 2016

Press Release

Regional Offices

Piramal Pharma Solutions Inc.

1500 Bull Lea Road

Suite 250,

Lexington, KY 40511

United States of America

+1 859 977 8600 www.piramalpharmasolutions.com
Piramal Healthcare UK Ltd

Whalton Road

NE61 3YA



United Kingdom

+44 1670 562400 +44 1670 562401 www.piramalpharmasolutions.com
Piramal Enterprises Limited

1st Floor, Piramal Agastya,

Opposite Fire brigade,

Kamani Junction, Kulra (West),

Mumbai : 400070


+91 22 3802 3000 www.piramalpharmasolutions.com

Go Top